Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Lajos Gera

TitleAssoc Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-BioChem&Molecular Genetics
Phone303/724-3336

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gera L, Charest-Morin X, Jean M, Bachelard H, Marceau F. Infrared-emitting, peptidase-resistant fluorescent ligands of the bradykinin B2 receptor: application to cytofluorometry and imaging. BMC Res Notes. 2016 Sep 26; 9(1):452. PMID: 27670785.
      View in: PubMed
    2. Zhang S, Gera L, Mamouni K, Li X, Chen Z, Kucuk O, Wu D. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. Oncotarget. 2016 May 10; 7(19):27489-98. PMID: 27050371.
      View in: PubMed
    3. Moran CS, Rush CM, Dougan T, Jose RJ, Biros E, Norman PE, Gera L, Golledge J. Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse. Arterioscler Thromb Vasc Biol. 2016 May; 36(5):898-907. PMID: 26966276.
      View in: PubMed
    4. Jiang Z, Gera L, Mant CT, Hirsch B, Yan Z, Qian Z, Holmes KV, Shortt JA, Pollock DD, Hodges RS. Platform technology to generate broadly cross-reactive antibodies to a-helical epitopes in hemagglutinin proteins from influenza a viruses. Biopolymers. 2016 Jan 21. PMID: 26799790.
      View in: PubMed
    5. Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2015; 6:306. PMID: 26793104; PMCID: PMC4709452.
    6. Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, Vassetzky Y, Kavsan V. Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds. Bioorg Med Chem. 2014 Aug 01; 22(15):3815-23. PMID: 25012567.
      View in: PubMed
    7. Gera L, Roy C, Charest-Morin X, Marceau F. Vasopeptidase-activated latent ligands of the histamine receptor-1. Int Immunopharmacol. 2013 Nov; 17(3):677-83. PMID: 24016859.
      View in: PubMed
    8. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med. 2013 Aug 28; 5(200):200ra117. PMID: 23986401; PMCID: PMC4016764.
    9. Gera L, Roy C, Marceau F. Bifunctional epitope-agonist ligands of the bradykinin B(2) receptor. Biol Chem. 2013 Mar; 394(3):379-83. PMID: 23241671.
      View in: PubMed
    10. Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, Gaudreault RC, Marceau F. Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B2 receptor cycling. Pharmacol Res. 2013 May; 71:44-52. PMID: 23454239.
      View in: PubMed
    11. Whalley ET, Figueroa CD, Gera L, Bhoola KD. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov. 2012 Dec; 7(12):1129-48. PMID: 23095011.
      View in: PubMed
    12. Gera L, Roy C, Bawolak MT, Charest-Morin X, Marceau F. N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Peptides. 2012 Apr; 34(2):433-46. PMID: 22349904.
      View in: PubMed
    13. Bawolak MT, Roy C, Gera L, Marceau F. Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins. Pharmacol Res. 2012 Feb; 65(2):247-53. PMID: 22108573.
      View in: PubMed
    14. Roy C, Marceau E, Gera L, Marceau F. An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B1 receptor in response to angiotensin converting enzyme inhibition. Vascul Pharmacol. 2012 Aug 19; 57(1):15-23. PMID: 21986309.
      View in: PubMed
    15. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, Long CS, Voelkel NF, Nicolls MR. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res. 2011 Sep 30; 109(8):867-79. PMID: 21868697; PMCID: PMC3204361.
    16. Gera L, Roy C, Bawolak MT, Bouthillier J, Adam A, Marceau F. Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. Pharmacol Res. 2011 Nov; 64(5):528-34. PMID: 21864683.
      View in: PubMed
    17. Pyrgaki C, Bannister SJ, Gera L, Gerber JG, Gal J. Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection. Chirality. 2011 Aug; 23(7):495-503. PMID: 21671287.
      View in: PubMed
    18. Jiang Z, Vasil AI, Gera L, Vasil ML, Hodges RS. Rational design of a-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants,' total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem Biol Drug Des. 2011 Apr; 77(4):225-40. PMID: 21219588; PMCID: PMC3063396.
    19. Gera L, Bawolak MT, Roy C, Lodge R, Marceau F. Design of fluorescent bradykinin analogs: application to imaging of B2 receptor-mediated agonist endocytosis and trafficking and angiotensin-converting enzyme. J Pharmacol Exp Ther. 2011 Apr; 337(1):33-41. PMID: 21205920.
      View in: PubMed
    20. Jutras S, Bachvarova M, Keita M, Bascands JL, Mes-Masson AM, Stewart JM, Gera L, Bachvarov D. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action. FEBS J. 2010 Dec; 277(24):5146-60. PMID: 21078129.
      View in: PubMed
    21. Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J. Vascular smooth muscle contractility assays for inflammatory and immunological mediators. Int Immunopharmacol. 2010 Nov; 10(11):1344-53. PMID: 20831918.
      View in: PubMed
    22. Koumbadinga GA, Bawolak MT, Marceau E, Adam A, Gera L, Marceau F. A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells. Peptides. 2010 Aug; 31(8):1546-54. PMID: 20452384.
      View in: PubMed
    23. Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F. Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors. Br J Pharmacol. 2009 Nov; 158(5):1375-86. PMID: 19785654; PMCID: PMC2782347.
    24. Bawolak MT, Gera L, Morissette G, Bouthillier J, Stewart JM, Gobeil LA, Lodge R, Adam A, Marceau F. Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther. 2009 Apr; 329(1):159-68. PMID: 19136639.
      View in: PubMed
    25. Gera L, Chan DC, Simkeviciene V, Bunn PA, Stewart JM. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. Adv Exp Med Biol. 2009; 611:465-6. PMID: 19400267.
      View in: PubMed
    26. Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, Chung LW, Wu D. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. Clin Cancer Res. 2008 Oct 01; 14(19):6198-206. PMID: 18829499.
      View in: PubMed
    27. Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, Mani S. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol. 2008 Sep; 74(3):662-72. PMID: 18579710.
      View in: PubMed
    28. Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Budunova I. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res. 2008 Jun 15; 68(12):4763-73. PMID: 18559523.
      View in: PubMed
    29. Bawolak MT, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F. A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides. 2008 Sep; 29(9):1626-30. PMID: 18565624.
      View in: PubMed
    30. Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther. 2007 Nov; 323(2):534-46. PMID: 17699739.
      View in: PubMed
    31. Gera L, Stewart JM, Fortin JP, Morissette G, Marceau F. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958. Int Immunopharmacol. 2008 Feb; 8(2):289-92. PMID: 18182242.
      View in: PubMed
    32. Morissette G, Houle S, Gera L, Stewart JM, Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol. 2007 Feb; 150(3):369-79. PMID: 17179948; PMCID: PMC2013894.
    33. Fortin JP, Dziadulewicz EK, Gera L, Marceau F. A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor. Mol Pharmacol. 2006 Apr; 69(4):1146-57. PMID: 16407468.
      View in: PubMed
    34. Gera L, Fortin JP, Adam A, Stewart JM, Marceau F. Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism. J Pharmacol Exp Ther. 2006 Apr; 317(1):300-8. PMID: 16368899.
      View in: PubMed
    35. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, Taraseviciene-Stewart L. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides. 2005 Aug; 26(8):1288-91. PMID: 15878795.
      View in: PubMed
    36. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides. 2005 Aug; 26(8):1292-300. PMID: 15878794.
      View in: PubMed
    37. Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F. Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther. 2005 Sep; 314(3):1169-76. PMID: 15919764.
      View in: PubMed
    38. Bironaite D, Gera L, Stewart JM. Characterization of the B2 receptor and activity of bradykinin analogs in SHP-77 cell line by Cytosensor microphysiometer. Chem Biol Interact. 2004 Dec 07; 150(3):283-93. PMID: 15560894.
      View in: PubMed
    39. Stewart JM, Gera L, Chan DC, York EJ, Stewart LT, Simkeviciene V, Helfrich B. New lung cancer drugs from bradykinin antagonists. Chest. 2004 May; 125(5 Suppl):148S. PMID: 15136471.
      View in: PubMed
    40. Tschöpe C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, Dhayat S, Bascands JL, Gera L, Hoffmann S, Schultheiss HP, Walther T. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res. 2004 Feb 15; 61(3):559-69. PMID: 14962486.
      View in: PubMed
    41. Cadnapaphornchai MA, Rogachev B, Summer SN, Chen YC, Gera L, Stewart JM, Schrier RW. Evidence for bradykinin as a stimulator of thirst. Am J Physiol Renal Physiol. 2004 May; 286(5):F875-80. PMID: 15075183.
      View in: PubMed
    42. Schroeder C, Breit A, Böning H, Dedio J, Gera L, Stewart J, Müller-Esterl W. Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin. Am J Physiol Heart Circ Physiol. 2003 Jun; 284(6):H1924-32. PMID: 12574004.
      View in: PubMed
    43. Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF. Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats. Am J Respir Crit Care Med. 2003 Jun 01; 167(11):1516-21. PMID: 12522028.
      View in: PubMed
    44. Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol. 2002 Dec; 2(13-14):1781-6. PMID: 12489792.
      View in: PubMed
    45. Todorov AG, Andrade D, Pesquero JB, Araujo Rde C, Bader M, Stewart J, Gera L, Müller-Esterl W, Morandi V, Goldenberg RC, Neto HC, Scharfstein J. Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J. 2003 Jan; 17(1):73-5. PMID: 12424228.
      View in: PubMed
    46. Mehok AR, Mant CT, Gera L, Stewart J, Hodges RS. Preparative reversed-phase liquid chromatography of peptides. Isocratic two-step elution system for high loads on analytical columns. J Chromatogr A. 2002 Sep 27; 972(1):87-99. PMID: 12395949.
      View in: PubMed
    47. Havass J, Bakos K, Márki A, Gáspár R, Gera L, Stewart JM, Fülöp F, Tóth GK, Zupkó I, Falkay G. Noncompetitive nature of oxytocin antagonists with general structure Mpa(1)Xxx(2)Sar(7)Arg(8). Peptides. 2002 Aug; 23(8):1419-25. PMID: 12182942.
      View in: PubMed
    48. Nguyen HH, Imhof D, Kronen M, Schlegel B, Härtl A, Gräfe U, Gera L, Reissmann S. Synthesis and biological evaluation of analogues of the peptaibol ampullosporin A. J Med Chem. 2002 Jun 20; 45(13):2781-7. PMID: 12061880.
      View in: PubMed
    49. Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May; 8(5):1280-7. PMID: 12006549.
      View in: PubMed
    50. Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci U S A. 2002 Apr 02; 99(7):4608-13. PMID: 11930011; PMCID: PMC123695.
    51. Stewart JM, Gera L, Chan DC, Bunn PA, York EJ, Simkeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002 Apr; 80(4):275-80. PMID: 12025961.
      View in: PubMed
    52. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol. 2002 Apr; 80(4):269-74. PMID: 12025960.
      View in: PubMed
    53. Miskolzie M, Gera L, Stewart JM, Kotovych G. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity. J Biomol Struct Dyn. 2002 Feb; 19(4):585-93. PMID: 11843620.
      View in: PubMed
    54. Banik RK, Kozaki Y, Sato J, Gera L, Mizumura K. B2 receptor-mediated enhanced bradykinin sensitivity of rat cutaneous C-fiber nociceptors during persistent inflammation. J Neurophysiol. 2001 Dec; 86(6):2727-35. PMID: 11731532.
      View in: PubMed
    55. Pan W, Kastin AJ, Gera L, Stewart JM. Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice. Neurosci Lett. 2001 Jul 06; 307(1):25-8. PMID: 11516566.
      View in: PubMed
    56. Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA, Vavrek RJ. Metabolism-resistant bradykinin antagonists: development and applications. Biol Chem. 2001 Jan; 382(1):37-41. PMID: 11258669.
      View in: PubMed
    57. Larrivée JF, Gera L, Houle S, Bouthillier J, Bachvarov DR, Stewart JM, Marceau F. Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol. 2000 Nov; 131(5):885-92. PMID: 11053207; PMCID: PMC1572413.
    58. Miskolzie M, Gera L, Stewart JM, Kotovych G. The importance of the N-terminal beta-turn in bradykinin antagonists. J Biomol Struct Dyn. 2000 Oct; 18(2):249-60. PMID: 11089646.
      View in: PubMed
    59. Reissmann S, Pineda F, Vietinghoff G, Werner H, Gera L, Stewart JM, Paegelow I. Structure activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine. Peptides. 2000 Apr; 21(4):527-33. PMID: 10822108.
      View in: PubMed
    60. Stewart JM, Gera L, York EJ, Chan DC, Bunn P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology. 1999 Sep; 43(2-3):155-61. PMID: 10596848.
      View in: PubMed
    61. Sejbal J, Wang Y, Cann JR, Stewart JM, Gera L, Kotovych G. A comparative NMR and molecular dynamics study of the conformations of bradykinin B1 and B2, B2, and B1-specific receptor antagonists B-9430, B-9436, and B-9858. Biopolymers. 1997 Oct 15; 42(5):521-35. PMID: 9322442.
      View in: PubMed
    62. Wieczorek M, Pilyavskaya A, Burkard M, Zuzack JS, Jones SW, Francis MD, Beckey VE, Ross SE, Goodfellow VS, Fitzpatrick TD, Marathe MV, Gyorkos A, Spruce LW, Selig WM, Stewart JM, Gera L, Whalley ET. Bradykinin antagonists in human systems: correlation between receptor binding, calcium signalling in isolated cells, and functional activity in isolated ileum. Biochem Pharmacol. 1997 Jul 15; 54(2):283-91. PMID: 9271333.
      View in: PubMed
    63. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS. Potent, long-acting bradykinin antagonists for a wide range of applications. Can J Physiol Pharmacol. 1997 Jun; 75(6):719-24. PMID: 9276154.
      View in: PubMed
    64. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS. Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications. Immunopharmacology. 1997 Jun; 36(2-3):167-72. PMID: 9228542.
      View in: PubMed
    65. Whalley ET, Hanson WL, Stewart JM, Gera L. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physiol Pharmacol. 1997 Jun; 75(6):629-32. PMID: 9276140.
      View in: PubMed
    66. Gera L, Stewart JM, Whalley ET, Burkard M, Zuzack JS. New bradykinin antagonists having very high potency at B1 receptors. Immunopharmacology. 1996 Jun; 33(1-3):183-5. PMID: 8856145.
      View in: PubMed
    67. Reissmann S, Greiner G, Seyfarth L, Paegelow I, Werner H, Vietinghoff G, Boeckmann S, Schulz E, Wartner U, Gera L. A new type of bradykinin B2 receptor antagonists: bradykinin analogs with N-alkyl amino acids at position 2. Immunopharmacology. 1996 Jun; 33(1-3):73-80. PMID: 8856118.
      View in: PubMed
    68. Chan D, Gera L, Helfrich B, Helm K, Stewart J, Whalley E, Bunn P. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharmacology. 1996 Jun; 33(1-3):201-4. PMID: 8856150.
      View in: PubMed
    69. Gera L, Stewart JM, Whalley E, Burkard M, Zuzack JS. A new class of potent bradykinin antagonist dimers. Immunopharmacology. 1996 Jun; 33(1-3):178-82. PMID: 8856144.
      View in: PubMed
    70. Sejbal J, Cann JR, Stewart JM, Gera L, Kotovych G. An NMR, CD, molecular dynamics and fluorometric study of the conformation of bradykinin antagonists B9340, B9430, B9436 and B9452 in water and in aqueous micellar solutions. Immunopharmacology. 1996 Jun; 33(1-3):198-200. PMID: 8856149.
      View in: PubMed
    71. Gera L, Stewart JM. A new class of bradykinin antagonists containing indanylglycine. Immunopharmacology. 1996 Jun; 33(1-3):174-7. PMID: 8856143.
      View in: PubMed
    72. Burkard M, Zuzack JS, Jones S, Francis M, Whalley ET, Stewart JM, Gera L. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors. Immunopharmacology. 1996 Jun; 33(1-3):186-90. PMID: 8856146.
      View in: PubMed
    73. Hanson WL, McCullough RG, Selig WM, Wieczorek M, Ross S, Whalley ET, Stewart JM, Gera L. In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors. Immunopharmacology. 1996 Jun; 33(1-3):191-3. PMID: 8856147.
      View in: PubMed
    74. Stewart JM, Gera L, Hanson W, Zuzack JS, Burkard M, McCullough R, Whalley ET. A new generation of bradykinin antagonists. Immunopharmacology. 1996 Jun; 33(1-3):51-60. PMID: 8856115.
      View in: PubMed
    75. Sejbal J, Cann JR, Stewart JM, Gera L, Kotovych G. An NMR, CD, molecular dynamics, and fluorometric study of the conformation of the bradykinin antagonist B-9340 in water and in aqueous micellar solutions. J Med Chem. 1996 Mar 15; 39(6):1281-92. PMID: 8632435.
      View in: PubMed
    76. Padmanabhan S, York EJ, Gera L, Stewart JM, Baldwin RL. Helix-forming tendencies of amino acids in short (hydroxybutyl)-L-glutamine peptides: an evaluation of the contradictory results from host-guest studies and short alanine-based peptides. Biochemistry. 1994 Jul 19; 33(28):8604-9. PMID: 8031795.
      View in: PubMed
    77. Cann JR, Liu X, Stewart JM, Gera L, Kotovych G. A CD and an NMR study of multiple bradykinin conformations in aqueous trifluoroethanol solutions. Biopolymers. 1994 Jul; 34(7):869-78. PMID: 8054469.
      View in: PubMed
    78. Bunn PA, Chan D, Stewart J, Gera L, Tolley R, Jewett P, Tagawa M, Alford C, Mochzuki T, Yanaihara N. Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines. Cancer Res. 1994 Jul 01; 54(13):3602-10. PMID: 7516822.
      View in: PubMed
    79. Liu X, Stewart JM, Cann JR, Gera L, Kotovych G. The aggregation properties of some bradykinin analogs. J Biomol Struct Dyn. 1993 Aug; 11(1):169-79. PMID: 8216942.
      View in: PubMed
    80. Pugh KC, Gera L, Stewart JM. Synthesis and stability of 3-nitro-2-pyridinesulfenyl chloride (NpysCl). Int J Pept Protein Res. 1993 Aug; 42(2):159-64. PMID: 8407109.
      View in: PubMed
    81. Liu X, Stewart JM, Gera L, Kotovych G. Proton magnetic resonance studies of bradykinin antagonists. Biopolymers. 1993 Aug; 33(8):1237-47. PMID: 8364157.
      View in: PubMed
    82. Vavrek RJ, Gera L, Stewart JM. Bradykinin antagonists do not require a D-aromatic amino acid residue at position 7. Agents Actions Suppl. 1992; 38 ( Pt 1):572-81. PMID: 1466298.
      View in: PubMed
    83. Vavrek RJ, Gera L, Stewart JM. Pseudopeptide analogs of bradykinin and bradykinin antagonists. Agents Actions Suppl. 1992; 38 ( Pt 1):565-71. PMID: 1466297.
      View in: PubMed
    84. Hammer RP, Albericio F, Gera L, Barany G. Practical approach to solid-phase synthesis of C-terminal peptide amides under mild conditions based on a photolysable anchoring linkage. Int J Pept Protein Res. 1990 Jul; 36(1):31-45. PMID: 2401599.
      View in: PubMed
    Gera's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)